MBX Biosciences Secures $440M Funding, Progresses Canvuparatide Phase 3 for Q3 Start
MBX Biosciences reported $440 million cash to fund operations into 2029, alongside a first-quarter net loss of $23.5 million. Once-weekly canvuparatide Phase 2 data will be presented at ENDO 2026, and the Phase 3 trial is on track for Q3 2026 after appointing a new CCO.
1. Q1 Financial Results and Cash Runway
MBX reported cash, cash equivalents and marketable securities of $440.0 million as of March 31, 2026, expected to fund operations into 2029. Research and development expenses were $18.5 million, general and administrative expenses rose to $8.8 million, and net loss totalled $23.5 million compared with $23.9 million a year earlier.
2. Advancing Canvuparatide and Obesity Pipeline
Results from the 12-week Avail Phase 2 trial and one-year open-label extension for once-weekly canvuparatide will be presented at ENDO 2026, with a Phase 3 confirmatory trial set to initiate in Q3 2026. MBX plans to nominate an amycretin prodrug this quarter and a GLP-1/GIP/GCGR triple-agonist prodrug candidate in Q3, with Phase 1 MBX 4291 data due in Q4 2026.
3. Leadership and Corporate Events
Mark Soued joined as Chief Commercial Officer, bringing extensive launch and commercialization expertise from biopharma leadership roles. MBX will host Obesity Day on May 11 to showcase initial blinded data from the MBX 4291 trial and provide updates on its expanding obesity portfolio.